Solid Biosciences Inc [SLDB] stock prices are up 4.47% to $4.91 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The SLDB shares have gain 13.13% over the last week, with a monthly amount drifted -12.63%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Solid Biosciences Inc [NASDAQ: SLDB] stock has seen the most recent analyst activity on June 26, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $14. Previously, Truist started tracking the stock with Buy rating on January 08, 2025, and set its price target to $16. On December 13, 2024, Wedbush initiated with an Outperform rating and assigned a price target of $16 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $15 on December 10, 2024. JP Morgan upgraded its rating to an Overweight and raised its price target to $15 on July 15, 2024. Leerink Partners upgraded its rating to Outperform for this stock on June 24, 2024, but kept the price target unchanged to $12.
The stock price of Solid Biosciences Inc [SLDB] has been fluctuating between $2.41 and $7.37 over the past year. Currently, Wall Street analysts expect the stock to reach $12.5 within the next 12 months. Solid Biosciences Inc [NASDAQ: SLDB] shares were valued at $4.91 at the most recent close of the market. An investor can expect a potential return of 154.58% based on the average SLDB price forecast.
Analyzing the SLDB fundamentals
Gross Profit Margin for this corporation currently stands at -0.53% with Operating Profit Margin at -54.32%, Pretax Profit Margin comes in at -53.5%, and Net Profit Margin reading is -53.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.61, Equity is -0.74 and Total Capital is -0.71. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.71 points at the first support level, and at 4.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.04, and for the 2nd resistance point, it is at 5.18.
Ratios To Look Out For
It’s worth pointing out that Solid Biosciences Inc [NASDAQ:SLDB]’s Current Ratio is 6.74. On the other hand, the Quick Ratio is 6.74, and the Cash Ratio is 1.69.
Transactions by insiders
Recent insider trading involved Ganot Ilan, Director, that happened on Nov 10 ’25 when 3278.0 shares were sold. Chief Medical Officer, Brooks Gabriel completed a deal on Oct 20 ’25 to sell 2895.0 shares. Meanwhile, Director Kahn Clare bought 1860.0 shares on Mar 11 ’25.
